Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited
Key Takeaways
- Tirzepatide is not going away. Brand Mounjaro and Zepbound are widely available and Eli Lilly continues to expand capacity
- The confusion stems from the October 2024 FDA decision to remove tirzepatide from the shortage list, which narrowed compounded availability but did not affect brand supply
- Brand and compounded tirzepatide are two different categories with different regulatory status, different supply chains, and different availability pictures in 2026
- Eli Lilly's tirzepatide patents extend into the 2030s; generic competition is not imminent
- SURMOUNT-1 trial data shows 22.5% mean weight loss at 15 mg over 72 weeks for tirzepatide; this efficacy profile applies to brand product
Direct answer
No, tirzepatide is not going away. Brand Mounjaro and Zepbound, both manufactured by Eli Lilly, are widely available and supply has been stable since late 2024. The question typically arises from confusion with the FDA's October 2, 2024 decision to remove tirzepatide from the drug shortage list, which ended broad compounded availability through 503B outsourcing facilities. Compounded tirzepatide through 503A patient-specific pathways continues, and brand product has never been more available.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- The confusion: brand availability vs compounded availability
- What's happening with brand Mounjaro and Zepbound
- What happened to compounded tirzepatide
- The Eli Lilly capacity story
- FDA approvals for tirzepatide and what's coming next
- Pricing and access in 2026
- Patents, generics, and the long-term outlook
- The investigational pipeline: what's next after tirzepatide
- Decision framework
- FAQ
- Sources
The confusion: brand availability vs compounded availability
Searches for "is tirzepatide going away" spiked in late 2024 and early 2025, following coverage of the FDA's shortage-list decision. Most of the resulting articles conflated two distinct questions:
- Is brand tirzepatide (Mounjaro, Zepbound) going away? No. Brand supply is stable and growing.
- Is compounded tirzepatide going away? Partially. The shortage-based pathway ended; the 503A patient-specific pathway continues.
These are different products in regulatory terms even though the active ingredient is the same molecule. The article you are reading takes the first question seriously and treats it separately from the second.
What's happening with brand Mounjaro and Zepbound
Eli Lilly's tirzepatide products are among the most prescribed pharmaceuticals globally. As of Q1 2026:
- Mounjaro (tirzepatide for type 2 diabetes) is in full production with multiple dose strengths (2.5, 5, 7.5, 10, 12.5, 15 mg) available in pen and vial formats
- Zepbound (tirzepatide for obesity, and obesity-related OSA) is in full production across all dose strengths
- Eli Lilly's manufacturing footprint includes facilities in Concord, North Carolina; Research Triangle Park, North Carolina; Branchburg, New Jersey; and overseas plants
- The company has announced additional capacity expansions targeting 2026-2028
Pharmacy fill rates for both products have been at or near 100% since late 2024. The intermittent stockouts that characterized 2022-2023 are no longer the norm.
What happened to compounded tirzepatide
The compounded category went through a specific regulatory transition that is worth distinguishing from the brand story.
During the shortage period (December 2022 to October 2024), both 503A pharmacies and 503B outsourcing facilities were authorized to compound tirzepatide under the shortage exception. This drove the rise of telehealth platforms offering compounded GLP-1s at lower prices than brand alternatives.
When the FDA removed tirzepatide from the shortage list on October 2, 2024, the shortage-based compounding authority ended. 503B outsourcing facilities had to wind down tirzepatide production. 503A pharmacies could continue compounding for individual patients, but only with documented clinical justification.
The Outsourcing Facilities Association challenged the FDA's decision in federal court. The Northern District of Texas ruled in favor of the FDA on March 5, 2025, foreclosing the 503B pathway.
What this means in practice: compounded tirzepatide is still available through 503A pharmacies for patients with documented clinical reasons, but the broad availability that characterized 2022-2024 has narrowed. Patients without specific clinical justification for compounded are typically directed to brand Zepbound or Mounjaro, increasingly through self-pay manufacturer programs.
The Eli Lilly capacity story
Understanding why "is tirzepatide going away" became a search term requires understanding the capacity arc.
From late 2022 through 2023, Eli Lilly could not produce tirzepatide fast enough. Mounjaro had launched in May 2022 for type 2 diabetes; Zepbound launched in November 2023 for obesity. Demand for both massively exceeded the company's initial capacity.
The investment response was unusual in scale. Eli Lilly committed more than $20 billion to U.S. manufacturing expansions between 2020 and 2025, with a substantial portion targeted at tirzepatide production. The Concord, North Carolina facility (announced 2020, operational 2023) was joined by Research Triangle Park (operational 2024) and additional expansions in Indianapolis and Lebanon, Indiana.
By Q3 2024, supply had caught up. The FDA reviewed the data and removed tirzepatide from the shortage list. The "going away" search trend emerged from coverage that emphasized the loss of compounded availability without distinguishing it from the brand availability picture.
FDA approvals for tirzepatide and what's coming next
Tirzepatide's regulatory trajectory has expanded since the original 2022 approval:
| Date | FDA Action | Indication |
|---|---|---|
| May 2022 | Original approval | Mounjaro for type 2 diabetes |
| November 2023 | Approval | Zepbound for chronic weight management in adults with obesity |
| December 2024 | Expanded approval | Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity |
| Expected 2026-2027 | Under review or in trials | Possible additional indications including MASH (metabolic dysfunction-associated steatohepatitis), heart failure with obesity, chronic kidney disease |
An expanding indication set strengthens, rather than weakens, the long-term outlook for tirzepatide as a category. Each new approval brings additional patient populations and adds clinical trial data supporting the molecule.
Pricing and access in 2026
Pricing has shifted in three ways since the shortage resolution.
First, list prices for brand Zepbound and Mounjaro have remained roughly stable, with manufacturer rebates negotiated separately with payers. Self-pay retail through major pharmacies typically runs $1,000-$1,300 per month.
Second, LillyDirect (Eli Lilly's direct-to-consumer platform, launched January 2024) introduced vial pricing for self-pay patients. As of mid-2026, the 2.5 mg, 5 mg, 7.5 mg, and 10 mg vials are available at $349, $499, $599, and $699 per month respectively. This is below pharmacy retail and represents a meaningful new self-pay option.
Third, compounded tirzepatide through 503A pharmacies typically runs $250-$500 monthly for patients with documented clinical justification. The cost gap between compounded and self-pay brand has narrowed substantially.
Patents, generics, and the long-term outlook
Eli Lilly holds multiple patents covering tirzepatide. The composition-of-matter patent on the molecule itself extends through approximately 2036, with method-of-use and manufacturing patents potentially extending further. Generic competition is not expected before the early 2030s at the earliest, and the timing depends on patent challenges and regulatory exclusivity periods.
What this means for the "going away" question: tirzepatide as a brand-name molecule will likely remain the dominant product in its category through at least the late 2020s. Generic versions will eventually emerge, but they will be additional options, not a discontinuation of the molecule.
The investigational pipeline: what's next after tirzepatide
Several investigational drugs are in advanced trials that could affect the tirzepatide market over the next 3-5 years.
Retatrutide (Eli Lilly) is a triple agonist (GLP-1, GIP, glucagon) in Phase 3 trials. Early data suggested weight loss potentially exceeding tirzepatide in some patient populations. This medication is investigational and not FDA-approved. FormBlends does not sell or supply retatrutide.
Orforglipron (Eli Lilly) is an oral small-molecule GLP-1 agonist in Phase 3 trials. If approved, it would represent the first oral GLP-1 with weight-loss efficacy approaching the injectables. This medication is investigational and not FDA-approved. FormBlends does not sell or supply orforglipron.
Cagrisema (Novo Nordisk) is a combination of cagrilintide (an amylin analog) and semaglutide. Phase 3 trials are ongoing. This medication is investigational and not FDA-approved. FormBlends does not sell or supply cagrisema.
None of these displaces tirzepatide. They are additions to the category that may differentiate on dosing, route of administration, or specific patient profiles. Tirzepatide is likely to remain a primary first-line option for several years.
Decision framework
If you read "tirzepatide is going away" and worried: The brand drug is not going away. The compounded category narrowed in October 2024 but did not close. Both pathways remain available with appropriate clinical fit.
If you are starting tirzepatide therapy: Brand Zepbound or Mounjaro is the default, accessible through insurance or LillyDirect self-pay. Compounded is appropriate when an individualized clinical reason exists.
If you have been on compounded tirzepatide: Ask your prescriber whether your chart documents clinical justification. If not, evaluate the LillyDirect self-pay vial pricing as an alternative.
If you are watching the regulatory landscape: Tirzepatide is firmly established. The bigger question is which investigational drugs reach approval and how they integrate into the existing standard of care.
FAQ
Is tirzepatide going away?
No. Brand product is widely available; compounded category narrowed but did not close.
Are Mounjaro and Zepbound still being made?
Yes, with expanded production capacity.
Did Eli Lilly stop making Mounjaro?
No.
Why do some people think tirzepatide is going away?
Confusion with the October 2024 shortage resolution and its effect on compounded availability.
Is there still a tirzepatide shortage?
No. The FDA resolved the shortage on October 2, 2024.
Will tirzepatide be discontinued?
Not in any foreseeable timeframe.
Can I still get a tirzepatide prescription in 2026?
Yes, brand or compounded (with documented clinical reason) through appropriate channels.
Is the patent expiring soon?
No. Patents extend into the 2030s.
What about new GLP-1 drugs replacing tirzepatide?
Investigational drugs are additions to the category, not replacements.
Does insurance still cover tirzepatide?
Coverage varies by plan and indication; LillyDirect self-pay is an alternative.
Sources
- FDA Drug Shortage List, October 2, 2024 resolution notice
- Eli Lilly press releases on manufacturing expansion, 2020-2025
- Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, July 2022 (SURMOUNT-1)
- Mounjaro FDA prescribing information, May 2022 with subsequent updates
- Zepbound FDA prescribing information, November 2023 with subsequent updates
- FDA approval of Zepbound for obstructive sleep apnea, December 2024
- Outsourcing Facilities Association v. FDA ruling, March 5, 2025
- Eli Lilly LillyDirect platform announcement, January 2024
- Eli Lilly Q4 2025 manufacturing capacity disclosure, investor relations
- U.S. Patent and Trademark Office records on tirzepatide patents
- Federal Food, Drug, and Cosmetic Act Section 503A and 503B provisions
- Retatrutide Phase 3 trial registrations (clinicaltrials.gov)
- Orforglipron Phase 3 trial registrations (clinicaltrials.gov)
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed clinicians for evaluation and prescription of GLP-1 therapy. We do not manufacture medications or replace the prescriber-patient relationship. Eligibility and prescribing decisions are made by licensed clinicians.
Compounded Medication Notice. Compounded tirzepatide is prepared by 503A pharmacy partners for individual patients based on prescriber documentation. It is not FDA-approved and is not bioequivalent to brand Mounjaro or Zepbound in a regulatory sense. The SURMOUNT clinical trial data applies to brand product.
Results Disclaimer. Weight outcomes vary individually. SURMOUNT-1 reported a 22.5% mean weight loss at the 15 mg dose over 72 weeks. Your result will depend on dose, adherence, baseline weight, lifestyle, and individual response.
Trademark Notice. Mounjaro, Zepbound, SURMOUNT, and LillyDirect are trademarks or service marks of Eli Lilly and Company. FormBlends is not affiliated with Eli Lilly.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →